Physician profile
Cherie E Simpson
NPI 1720030307
$5,084.71
in general payments reported to CMS, 2019-2025
23 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 99% of Psychiatric/Mental Health, Geropsychiatric providers received nationally (typical 2025 total: $510).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $895 · 2022: $814 · 2023: $1,181 · 2024: $1,069 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $859.55 | 2022-2025 | Spravato |
| Lundbeck LLC | $584.13 | 2021-2025 | Rexulti, Brintellix, Vyepti |
| Eisai INC. | $542.01 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $380.18 | 2021-2025 | Rexulti, Abilify Mycite |
| Neurocrine Biosciences, INC. | $327.93 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $302.16 | 2023-2025 | Auvelity |
| Acadia Pharmaceuticals INC | $279.59 | 2021-2025 | Nuplazid |
| Lilly USA, LLC | $277.35 | 2022-2025 | Kisunla, Amyvid |
| Abbvie INC. | $275.94 | 2021-2025 | |
| Biogen, INC. | $270.55 | 2021-2025 | Leqembi, Aduhelm |
| Teva Pharmaceuticals USA, INC. | $269.20 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $217.92 | 2021-2025 | Trintellix |
| Corium, LLC | $160.43 | 2022-2023 | Adlarity |
| Vanda Pharmaceuticals INC. | $66.73 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $53.55 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $42.95 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $36.50 | 2021 | |
| Merck Sharp & Dohme LLC | $36.43 | 2021-2022 | |
| Life Molecular Imaging Ltd | $27.20 | 2023 | Neuraceq |
| Almatica Pharma LLC | $22.44 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.23 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.95 | 2022 | |
| Alfasigma USA, INC. | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherie Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.